472 related articles for article (PubMed ID: 16059699)
21. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Wang MZ; Tai CY; Mendel DB
Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
[TBL] [Abstract][Full Text] [Related]
22.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
23. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
[TBL] [Abstract][Full Text] [Related]
24. Perspectives on antiviral use during pandemic influenza.
Hayden FG
Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1877-84. PubMed ID: 11779387
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Boivin G; Goyette N
Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
[TBL] [Abstract][Full Text] [Related]
26. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza.
Dreitlein WB; Maratos J; Brocavich J
Clin Ther; 2001 Mar; 23(3):327-55. PubMed ID: 11318072
[TBL] [Abstract][Full Text] [Related]
27. Neuraminidase inhibitors as antiviral agents.
Alymova IV; Taylor G; Portner A
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
[TBL] [Abstract][Full Text] [Related]
28. [Neuraminidase inhibitor].
Kaji M
Nihon Rinsho; 2000 Nov; 58(11):2293-8. PubMed ID: 11225320
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Gubareva LV; Penn CR; Webster RG
Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
[TBL] [Abstract][Full Text] [Related]
30. In vitro efficacies of oseltamivir carboxylate and zanamivir against equine influenza A viruses.
Yamanaka T; Tsujimura K; Kondo T; Matsumura T
J Vet Med Sci; 2006 Apr; 68(4):405-8. PubMed ID: 16679737
[TBL] [Abstract][Full Text] [Related]
31. Updated treatment for influenza A and B.
Montalto NJ; Gum KD; Ashley JV
Am Fam Physician; 2000 Dec; 62(11):2467-76. PubMed ID: 11130232
[TBL] [Abstract][Full Text] [Related]
32. [Critical review of anti-influenza drugs].
van Loon FP; Voordouw AC; Simonian S; Koopmans PP
Ned Tijdschr Geneeskd; 2000 Jan; 144(4):165-7. PubMed ID: 10668542
[TBL] [Abstract][Full Text] [Related]
33. Neuraminidase inhibitors: zanamivir and oseltamivir.
McNicholl IR; McNicholl JJ
Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
[TBL] [Abstract][Full Text] [Related]
34. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Wutzler P; Kossow KD; Lode H; Ruf BR; Scholz H; Vogel GE;
J Clin Virol; 2004 Oct; 31(2):84-91. PubMed ID: 15364262
[TBL] [Abstract][Full Text] [Related]
35. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of newer treatment strategies for influenza.
Smith KJ; Roberts MS
Am J Med; 2002 Sep; 113(4):300-7. PubMed ID: 12361816
[TBL] [Abstract][Full Text] [Related]
37. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
38. Neuraminidase inhibitors for the treatment and prevention of influenza.
McKimm-Breschkin JL
Expert Opin Pharmacother; 2002 Feb; 3(2):103-12. PubMed ID: 11829724
[TBL] [Abstract][Full Text] [Related]
39. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
40. Review of the use of neuraminidase inhibitors for prophylaxis of influenza.
Kirkbride HA; Watson J
Commun Dis Public Health; 2003 Jun; 6(2):123-7. PubMed ID: 12889291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
